The forecast for antacid medicine sales in Germany shows a stable per capita expenditure at $0.4 (PPP) for both 2024 and 2025, with a slight increase to $0.5 expected from 2026 to 2028. Compared to 2023, these forecasts suggest modest year-on-year growth starting in 2026. Given that the CAGR over this five-year span reflects the minimal projected change, it indicates a steady but unremarkable growth trajectory in this market. Variations in previous years remain modest, emphasizing a prolonged plateau in consumer spending.

Future trends to watch include:

Potential influence of public health initiatives on digestive health and antacid usage.
The impact of emerging competitors and new product innovations.
Regulatory changes affecting product availability and pricing.